Assembly Biosciences (ASMB) Stock Price, Quote & News

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 509 4583

Website: www.assemblybio.com

Address:

Two Tower Place, 7th Floor, South San Francisco, United States

turbjade Sep. 12 at 5:08 PM

$ASMB market seems to think this needs to drop around $21.3-$21.5, it's a buy here, it's a screaming buy in that range

0 · Reply

Dachshundtrader Sep. 12 at 5:17 AM

$ASMB

0 · Reply

HighReturnStocks Sep. 12 at 1:28 AM

$ASMB added more this week. Should reverse soon

0 · Reply

StockBarG Sep. 11 at 7:03 PM

$ASMB in at 22.35

0 · Reply

NVDAMillionaire Sep. 10 at 6:39 AM

$ASMB Excellent article that nails exactly where ASMB stands right now. So if you want to update your ASMB knowledge or get acquainted with ASMB, this is a must read. https://beyondspx.com/quote/ASMB/analysis/assembly-bio-s-antiviral-breakthrough-clinical-momentum-and-strategic-capital-fuel-a-new-growth-chapter-nasdaq-asmb

0 · Reply

onemillion2012 Sep. 10 at 5:01 AM

$ASMB this will revisit year high in next 2 weeks

0 · Reply

intrader Sep. 9 at 4:40 PM

$ASMB I'm in.

0 · Reply

onemillion2012 Sep. 9 at 10:15 AM

$ASMB how many Germans on the board. Only like if you are German

1 · Reply

onemillion2012 Sep. 8 at 2:05 PM

$ASMB Onemillion2012 updates rating for Assembly Biosciences ( $ASMB ) to strong Buy, target set at 72 → 84.

0 · Reply

JarvisFlow Sep. 8 at 1:39 PM

Guggenheim updates rating for Assembly Biosciences ( $ASMB ) to Buy, target set at 31 → 39.

0 · Reply

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug 8, 2025, 8:05 AM EDT - 5 weeks ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:00 AM EDT - 5 weeks ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Jul 26, 2025, 3:00 AM EDT - 6 weeks ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 25, 2025, 8:00 AM EDT - 2 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

May 27, 2025, 4:05 PM EDT - 3 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 4 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 7, 2025, 8:00 AM EDT - 4 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Apr 9, 2025, 2:00 AM EDT - 5 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Mar 20, 2025, 4:05 PM EDT - 6 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Feb 26, 2025, 8:00 AM EST - 7 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 7 months ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 9 months ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Feb 8, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Nov 10, 2023, 4:05 PM EST - 2 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 2 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Jan 17, 2023, 7:00 AM EST - 2 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Oct 24, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 8, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

May 12, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Mar 10, 2022, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Feb 9, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Jan 7, 2022, 5:00 PM EST - 4 years ago

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2022, 8:00 AM EST - 4 years ago

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

Nov 12, 2021, 8:00 AM EST - 4 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

turbjade Sep. 12 at 5:08 PM

$ASMB market seems to think this needs to drop around $21.3-$21.5, it's a buy here, it's a screaming buy in that range

0 · Reply

Dachshundtrader Sep. 12 at 5:17 AM

$ASMB

0 · Reply

HighReturnStocks Sep. 12 at 1:28 AM

$ASMB added more this week. Should reverse soon

0 · Reply

StockBarG Sep. 11 at 7:03 PM

$ASMB in at 22.35

0 · Reply

NVDAMillionaire Sep. 10 at 6:39 AM

0 · Reply

onemillion2012 Sep. 10 at 5:01 AM

$ASMB this will revisit year high in next 2 weeks

0 · Reply

intrader Sep. 9 at 4:40 PM

$ASMB I'm in.

0 · Reply

onemillion2012 Sep. 9 at 10:15 AM

$ASMB how many Germans on the board. Only like if you are German

1 · Reply

onemillion2012 Sep. 8 at 2:05 PM

$ASMB Onemillion2012 updates rating for Assembly Biosciences ( $ASMB ) to strong Buy, target set at 72 → 84.

0 · Reply

JarvisFlow Sep. 8 at 1:39 PM

Guggenheim updates rating for Assembly Biosciences ( $ASMB ) to Buy, target set at 31 → 39.

0 · Reply

Dachshundtrader Sep. 5 at 7:47 PM

$ASMB Runway locked till 2027, GILD on board, HSV data 🔥 and HBV/HDV catalysts ahead. Tiny float + solid fundamentals = one of the cleanest mid-term biotech setups out there.

2 · Reply

HighReturnStocks Sep. 5 at 1:59 PM

$ASMB averaging up here to get more, Im liking this long term.

0 · Reply

onemillion2012 Sep. 4 at 2:58 PM

$ASMB down 12 percent last 5 days. The German masterpiece are selling out

0 · Reply

onemillion2012 Sep. 3 at 2:39 PM

$BCAB she is moving. Get in now at under 50 cent. Come friends from $VNDA $ASMB It's a double or triple in 2 monts

0 · Reply

Fugazi_ Sep. 2 at 4:38 PM

$ASMB Did this company just add a option chain?

1 · Reply

onemillion2012 Aug. 29 at 4:44 PM

$ASMB who are selling.. I think it is oure old Germen leader Alexander.

0 · Reply

onemillion2012 Aug. 28 at 7:35 AM

$ASMB check out this bad boy.. $BCAB ready to fly 100-200 percent. Get in before news about partnership. Coming soon

1 · Reply

onemillion2012 Aug. 28 at 5:24 AM

$ASMB maybe some of you have sold out of your position. If you have and got extra $$$ then take a look at $BCAB it is up 2 straight days on strong volume. Ready to explode. So my friends it is a really nice opportunity. Partnership is on the way for there lead phase 3 drug. My other positions $VNDA $ALIT $CROX $ALT

0 · Reply

ChartElite Aug. 27 at 6:49 AM

$ASMB pops after the biotech announced positive interim data for its hepatitis B program; traders eye the next catalyst and Chart Elite AI flags potential upside on the chart.

1 · Reply

Dachshundtrader Aug. 27 at 5:37 AM

$ASMB consolidating after strong news flow. 📊 Solid support seen in the low-20s, with $20–21 shaping up as an attractive add zone. Cash runway into 2027 + GILD on board → fundamentals remain intact. Great opportunity 😍

1 · Reply

Poldi2021 Aug. 26 at 8:50 PM

$ASMB did you See the huuuuge volumen in the last 15 minutes? More than 60000 Shares traded…amazing sign

1 · Reply

Jkwran69 Aug. 26 at 6:29 PM

$ASMB I don't understand the big drop today, just when it was getting momentum

1 · Reply

Market Cap	173.32M
Revenue (ttm)	28.52M
Net Income (ttm)	-40.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.88%
Debt to Equity Ratio	0.00

Volume	67,500
Avg Vol	100,878
Day's Range	N/A - N/A
Shares Out	7.67M
Stochastic %K	5%
Beta	0.68
Analysts	Strong Sell
Price Target	$38.25